Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 22Neoplasm Metastasis 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Lung Neoplasms 1HER2-positive Breast Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1

Interventions

Biopsy 2pertuzumab 1Vaccines 1Trastuzumab 1Therapeutics 1Risedronic Acid 1Mastectomy, Simple 1Mastectomy, Segmental 1Mammaplasty 1Ferric Oxide, Saccharated 1Cryosurgery 1Cholecalciferol 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Intraductal, Noninfiltrating × Trastuzumab × Clear all
NCT02336984 2021-01-11

A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Withdrawn
Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡